Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.57 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.57 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.57 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.57 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.57 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.57 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.57 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.57 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.57 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.57 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.57 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.57 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.57 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.57 |
| ▸ | PSMA6 | P60900 | 1/20 | 0.57 |
| ▸ | PSMA8 | Q8TAA3 | 1/20 | 0.57 |
| ▸ | PSMB7 | Q99436 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28102497 | 0.86 | TGM2 (0.56) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL5043916 | 0.81 | TGM2 (0.63) | TGM2EGFRITKALDH1A1SMN1; SMN2 | |
| SCHEMBL7954480 | 0.80 | ALDH1A1 (0.53) | HTTALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL29032649 | 0.80 | BCHE (0.59) | BCHEHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29663729 | 0.80 | MAPT (0.69) | EGFRHTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1381244 | 0.79 | TGM2 (0.59) | TGM2EGFRITKLMNA | |
| SCHEMBL9864914 | 0.79 | TGM2 (0.59) | TGM2EGFRITKHTTALDH1A1 | |
| SCHEMBL5041890 | 0.79 | TGM2 (0.69) | TGM2HTTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL6481952 | 0.78 | EGFR (0.62) | EGFRITK | |
| SCHEMBL2090421 | 0.78 | ATM (0.58) | HTTALDH1A1SMN1; SMN2HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648448-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | claimed |
| EP-1648448-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005011681-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | claimed |
| CN-110746355-B | Phenylpyrazole compound, pharmaceutical composition, and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2023-08-11 | — | — | CN | disclosed |
| CN-106008480-A | Quinazoline compound containing cinnamamide structure and preparation method and application thereof | 江西科技师范大学 | 2016-10-12 | — | — | CN | disclosed |
| CN-100497355-C | Hypophosphorous acid derivatives as beta-secretase inhibitors for the treatment of Alzheimer's disease | HOFFMANN LA ROCHE (CH) | 2009-06-10 | — | — | CN | disclosed |
| US-7345082-B2 | Phosphinic acids | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1685142-B1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1773310-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-04-18 | — | — | EP | disclosed |
| CN-1878781-A | Hypophosphorous acid derivatives as beta-secretase inhibitors for the treatment of Alzheimer's disease | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| EP-1685142-A1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2006025924-A2 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005044830-A1 | PHOSPHINIC ACIDS DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107341-A1 | Phosphinic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| US-4940711-A | Antihypertensive N-piperazinylalkanoylanilides | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1990-07-10 | — | — | US | disclosed |
| EP-0120558-A1 | Antihypertensive N-piperazinylalkanoylanilides | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107341-A1 | Phosphinic acids | BACE1, PSEN1, PSEN2 | PSMB11 1725/4885PSMA7 697/4885PSMB1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.